Steven Paul

Biography

Dr. Steven Paul is the recently retired Executive Vice President and President of the Lilly Research Laboratories of Eli Lilly and Company. Prior to this position, Dr. Paul was Group Vice President of Discovery Research and Clinical Investigation as well as Vice President of Neuroscience Discovery Research at Lilly. In his role as Lilly’s R&D leader Dr. Paul oversaw the R&D efforts of over 8,000 scientists and physician investigators. Prior to assuming his position at Lilly, Dr. Paul served as the Scientific Director of the National Institute of Mental Health (NIH). Dr. Paul is a neuropsychopharmacologist and psychiatrist by training and his own research has focused on novel therapeutic interventions for Alzheimer’s disease, depression and schizophrenia. Among his many scientific contributions has been the delineation of the role for the inhibitory neurotransmitter GABA in mediating the behavioral effects of benzodiazepines, barbiturates, short-chain alcohols and a novel class of neuroactive steroids. Dr. Paul has published over 500 papers and invited book chapters and holds 8 patents on inventions made at Lilly and NIH and is an inventor of solanezumab one of Lilly’s late-stage drug candidates for Alzheimer’s disease. 

Research Interest

Discovery Research and Clinical Investigation